Eisai Sees Generics Production In India Way To Make Affordable Drugs (Japan)
This article was originally published in PharmAsia News
An Eisai executive says the Japanese company is turning to India for expanded production of active pharmaceutical ingredients, in part because it cannot make drugs in Japan cheaply enough to make them affordable in poor countries. Takafumi Asano, an Esai vice president, also said the company expects to take advantage of production costs in India to make its own generics at a fraction of the price of its branded drugs. Asano added, during an interview along with Deputy President Soichi Matsuno, that the company would not be able to do so if it relied solely on its Kashima plant in Japan. The firm recently opened a second production plant for generics in India. (Click here for more - may require a subscription
You may also be interested in...
In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting.
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.